Date: 2013-09-03
Type of information: Services contract
Compound:
Company: Biofocus, a Galapagos Company (UK - Belgium) Aviva Investors (UK)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On September 3, 2013, BioFocus and Aviva Investors, the owners of Chesterford Research Park, have announced the signing of a pre-let agreement for the new Robinson Building, a 60,000 square foot (5,587 square metres) state-of-the-art laboratory facility at Chesterford. BioFocus will unite the majority of its drug discovery groups within the new complex, affording the company a unique position amongst CROs for support of integrated projects. As the Robinson Building already has outline planning permission, construction is expected to start on site almost immediately. The building has been designed as two wings, linked by a two-storey atrium and a landscaped courtyard.
Financial terms:
Latest news:
